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Background
Numerous studies have evaluated individual DNA plas-
mid vaccines. We evaluated data from 10 HIV vaccine
clinical trials that utilized common, validated immuno-
genicity assays to objectively investigate factors that
influence DNA plasmid-induced T-cell responses.
Methods
This retrospective analysis included data from 1218
healthy, HIV-1 uninfected adults enrolled in 10 DNA
HIV vaccine clinical trials conducted within the HIV
Vaccine Trials Network. HIV-specific T-cell responses
from peripheral blood mononuclear cells were measured
using validated IFN-g ELISpot and intracellular cytokine
staining assays. The effects of DNA vaccine HIV anti-
gens, number of doses, gender, body mass index (BMI),
and age were evaluated.
Results
When plasmids expressing Gag, Env and Pol were co-
administered, the highest T-cell response rate was against
Env (38.1%) and much less to Gag (4.6%) or Pol (4.5%).
Comparing 2, 3, and 4 DNA injections, 3 vaccinations
compared to 2 improved the magnitude of Env-specific
CD8+ T-cell response (p=0.048), but not CD4+ T-cell
responses, and a 4th vaccination had no additional effect.
HIV-specific CD4+ T-cell response rates were higher in
females (50.9%) than in males (27.7%, p=0.0002). Having
lower BMI (p=0.025) was independently associated with
higher HIV-specific CD4+ T-cell response rates. There
were no significant differences in HIV-specific CD8+
T-cell response frequencies by gender or BMI. Lower
HIV-specific CD4+ T-cell responses were seen with the
18-20 (36.4%) and 41-50 (23.3%) age groups compared to
the 21-30 (44.0%) and 31-40 (41.%) groups, but these
differences were not significant (p=0.0565) and no differ-
ences were seen in HIV-specific CD8+ T-cell responses
by age.
Conclusion
Pooled data across DNA HIV vaccine clinical trials indi-
cate that plasmid inserts, number of doses, gender, and
BMI can affect T-cell responses. These factors should be
considered in vaccine research.
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